Mumbai, Feb. 10 -- Lupin and its alliance partner Natco Pharma Limited (Natco), today announced that they have received an approval from the United States Food and Drug Administration (U.S. FDA) for Natco's Abbreviated New Drug Application (ANDA) for Bosentan Tablets for Oral Suspension, 32 mg, to market a generic equivalent of Tracleer(R) Tablets for Oral Suspension of Actelion Pharmaceuticals US, Inc. Natco is the exclusive first-to-file for this product and is eligible for 180 days exclusivity.

Published by HT Digital Content Services with permission from Capital Market....